每周一次替加环素治疗耐药结核病
该研究在结核分枝杆菌空心纤维模型中评估替加环素单药疗效。结果显示替加环素对对数生长期、半休眠及胞内菌均有杀菌作用,每周一次给药与每日给药疗效相同,疗效与AUC0-24/MIC相关;12个月单药治疗时64.51%的XDR-TB患者达到细菌种群灭绝。
要点
- 替加环素单药对对数生长期结核菌有效。
- 每周一次与每日给药在相同累积剂量下疗效相同。
- 12个月替加环素单药治疗可使部分XDR-TB患者达到细菌种群灭绝。
核心结论
- 替加环素单药可有效杀灭结核分枝杆菌,包括半休眠和胞内菌。
- 每周一次替加环素治疗在模型中对XDR-TB或MDR-TB治疗失败者可能有效。
研究设计与样本
- 采用空心纤维系统结核模型进行药代动力学/药效学研究。
- 共五项独立实验使用对数生长期、半休眠或胞内结核分枝杆菌进行替加环素单药研究。
- 比较替加环素与异烟肼/利福平/吡嗪酰胺优化标准方案的疗效。
主要发现
- 30株结核分枝杆菌临床和实验室分离株(67%为MDR/XDR)对替加环素的中位MIC为2 mg/L。
- 替加环素单药对对数生长期及半休眠和胞内结核分枝杆菌均高度有效。
- 相同累积剂量下每周一次给药与每日给药疗效相同,疗效与AUC0-24/MIC相关。
- 替加环素治疗4周后每日换用米诺环素可有效灭菌。
- 最佳杀菌的AUC0-24/MIC为42.3。
关键数值与推荐
- 替加环素单药最大灭菌效果(第0天减第28天)为3.06 ± 0.20 log10 cfu/mL(r2 = 0.92),优化标准治疗为3.92 ± 0.45 log10 cfu/mL(r2 = 0.80)。
- 在模型中替加环素单药治疗12个月时,XDR-TB患者达到细菌种群灭绝的比例为64.51%。
临床怎么用
- 替加环素可能治愈对推荐方案治疗失败的XDR-TB或MDR-TB患者。
- 每周一次替加环素可在MDR-TB方案中替代二线注射剂。
局限性
- 研究为空心纤维系统模型,非人体临床试验,结论需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: MDR-TB and XDR-TB have poor outcomes. OBJECTIVES: To examine the efficacy of tigecycline monotherapy in the hollow fibre system model of TB. METHODS: We performed pharmacokinetic/pharmacodynamic studies using tigecycline human-like concentration-time profiles in the hollow fibre system model of TB in five separate experiments using Mycobacterium tuberculosis in log-phase growth or as semi-dormant or intracellular bacilli, as monotherapy. We also compared efficacy with the isoniazid/rifampicin/pyrazinamide combination (standard therapy). We then applied extinction mathematics, morphisms and Latin hypercube sampling to identify duration of therapy with tigecycline monotherapy. RESULTS: The median tigecycline MIC for 30 M. tuberculosis clinical and laboratory isolates (67% MDR/XDR) was 2 mg/L. Tigecycline monotherapy was highly effective in killing M. tuberculosis in log-phase-growth and semi-dormant and intracellular M. tuberculosis. Once-a-week dosing had the same efficacy as daily therapy for the same cumulative dose; thus, tigecycline efficacy was linked to the AUC0-24/MIC ratio. Tigecycline replacement by daily minocycline after 4 weeks of therapy was effective in sterilizing bacilli. The AUC0-24/MIC ratio associated with optimal kill was 42.3. Tigecycline monotherapy had a maximum sterilizing effect (day 0 minus day 28) of 3.06 ± 0.20 log10 cfu/mL (r2 = 0.92) compared with 3.92 ± 0.45 log10 cfu/mL (r2 = 0.80) with optimized standard therapy. In our modelling, at a tigecycline monotherapy duration of 12 months, the proportion of patients with XDR-TB who reached bacterial population extinction was 64.51%. CONCLUSIONS: Tigecycline could cure patients with XDR-TB or MDR-TB who have failed recommended therapy. Once-a-week tigecycline could also replace second-line injectables in MDR-TB regimens.
引用
- Deshpande D, Magombedze G, Srivastava S, et al. Once-a-week tigecycline for the treatment of drug-resistant TB. J Antimicrob Chemother. 2019. PMID: 30820554. doi:10.1093/jac/dkz061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。